INOVIO to Participate in Upcoming Scientific Conferences

Rhea-AI Summary

INOVIO (NASDAQ: INO), a biotechnology company, has announced its participation in multiple upcoming scientific conferences to present data on its lead product candidate INO-3107 for Recurrent Respiratory Papillomatosis (RRP) and next-generation DNA medicine technology.

The company has initiated a rolling Biologics License Application (BLA) submission for INO-3107, with plans to complete the submission in H2 2025 and targeting FDA file acceptance by year-end. The presentations will take place across various conferences including the American Academy of Otolaryngology Annual Meeting, World Vaccine Congress Europe, and ESMO Congress.

Additionally, INOVIO will present the first preclinical data on DNA-encoded protein technology (DPROT) for Hemophilia A and showcase developments in DNA-encoded monoclonal antibody (DMAb) technology.

News Market Reaction

-3.57%

1 alert

-3.57% News Effect

On the day this news was published, INO declined 3.57%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

• Several presentations to highlight key aspects of lead product candidate, INO-3107, as a potential treatment for Recurrent Respiratory Papillomatosis (RRP)
• Additional presentations focus on promise of next-generation DNA medicine technology, including the first preclinical data describing potential for DNA-encoded protein technology (DPROT) to address Hemophilia A

PLYMOUTH MEETING, Pa., Sept. 25, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present data at a number of upcoming scientific conferences, highlighting key aspects of lead product candidate INO-3107 for RRP. INOVIO has begun the rolling submission of its Biologics License Application (BLA) for INO-3107, which it anticipates completing in the second half of 2025 with the goal of file acceptance by the U.S. Food and Drug Administration by the end of 2025.

INOVIO also plans to highlight its next-generation DNA-medicine technology, including presentations on a Phase 1 clinical trial of a DNA-encoded monoclonal antibody (DMAb) product candidate and new preclinical data on DPROTs addressing Hemophilia A.

Presentations on INO-3107 for RRP:

American Academy of Otolaryngology – Head and Neck Surgery Annual Meeting
Indianapolis
Date: October 11-13
Poster Title: DNA Immunotherapy (INO-3107) Demonstrates a Durable Response for Treatment of HPV-6/11 Recurrent Respiratory Papillomatosis

World Vaccine Congress Europe
Amsterdam, NL
Date: October 13
Time: 3:45 PM CEST
Presentation Title: Leveraging the Potential of DNA Immunotherapy: Long-Term Efficacy in HPV-6 & 11 Recurrent Respiratory Papillomatosis

European Society For Medical Oncology Congress
Berlin, DE
Date: October 19
Poster Title: DNA Immunotherapy (INO-3107) in HPV-6 & 11 Recurrent Respiratory Papillomatosis – Long-Term Efficacy

37th Annual International Papillomavirus Society Conference
Bangkok, TH
Date: October 24
Time: 2:40 - 2:55 PM ICT
Presentation Title: Clinical Response to INO-3107 in RRP is Irrespective of Papilloma Microenvironment and Molecular Subtype

Date: October 25
Time: 6:54 - 7:00 PM ICT
E-Poster Title: DNA Immunotherapy (INO-3107) Induces Persistent Immune Responses Resulting in Long-term Efficacy Through Post-Treatment Year 2 for HPV 6&11 RRP

International Society for Vaccines Annual Congress
Stellenbosch, SA
Date: October 30
Time: 10:20 - 10:35 AM SAST
Presentation Title: Immunotherapy, INO-3107, is Well-Tolerated, Effective, and Elicits an Antigen-Specific T-cell Response in Adults with HPV-6 & 11 Recurrent Respiratory Papillomatosis

Presentations on Next-Generation DNA Medicine:

European Society of Gene and Cell Therapy Congress
Seville, ES
Date: October 7-10
Poster Title: Employment of the CELLECTRA® in vivo gene delivery platform in a first in human (FIH) DNA encoded monoclonal antibody (DMAb) clinical trial

World Vaccine Congress Europe
Amsterdam, NL
Date: October 16
Time: 1:00 PM CET
Presentation Title: DMAb Technology: Next Generation DNA Medicine Design and Delivery

World Orphan Drug Congress
Amsterdam, NL
Date: October 29
Time: 11:10 AM CET
Presentation Title: DMAb Technology: The Transformational Potential of Next Gen DNA Medicine in Rare Disease

14th World Federation of Hemophilia Global Forum
Montreal, CA
Date: November 14
Time: 1:45 PM EST
Presentation Title: Novel FVIII Secretion Via Non-Viral Vector DNA Medicine Platform

Available abstracts will be shared on INOVIO's website following presentations.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-upcoming-scientific-conferences-302566500.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

When will INOVIO complete the BLA submission for INO-3107?

INOVIO plans to complete the rolling BLA submission for INO-3107 in the second half of 2025, with the goal of FDA file acceptance by the end of 2025.

What conferences will INOVIO present at regarding INO-3107?

INOVIO will present INO-3107 data at multiple conferences including the American Academy of Otolaryngology Annual Meeting, World Vaccine Congress Europe, ESMO Congress, International Papillomavirus Society Conference, and International Society for Vaccines Annual Congress.

What is INO-3107 being developed to treat?

INO-3107 is being developed as a potential treatment for Recurrent Respiratory Papillomatosis (RRP), a condition caused by HPV-6 and HPV-11.

What new technology will INOVIO present data on for Hemophilia A?

INOVIO will present the first preclinical data on its DNA-encoded protein technology (DPROT) for addressing Hemophilia A.